Physician profile
Devika Madhavan
NPI 1972923274
$732.50
in general payments reported to CMS, 2019-2025
16 companies · $39.39 in 2025
The $39.39 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67.96 · 2020: $326 · 2021: $260 · 2024: $39.44 · 2025: $39.39.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $78.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $78.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $169.50 | 2019-2021 | |
| Novo Nordisk INC | $124.99 | 2020-2021 | |
| Astrazeneca Pharmaceuticals Lp | $103.72 | 2020-2021 | |
| Insulet Corporation | $78.76 | 2020-2025 | Omnipod |
| Dexcom, INC. | $44.36 | 2020-2021 | |
| Amgen INC. | $33.07 | 2020-2025 | Tepezza |
| Ascensia Diabetes Care US INC. | $20.91 | 2021 | |
| Tandem Diabetes Care, INC. | $20.59 | 2019 | |
| Mannkind Corporation | $20.35 | 2020 | |
| Sanofi-Aventis U.S. LLC | $18.58 | 2020 | |
| Zealand Pharma US, INC. | $18.57 | 2020 | |
| Amarin Pharma, INC. | $17.48 | 2020 | |
| Medtronic Minimed, INC. | $17.20 | 2019 | |
| Xeris Pharmaceuticals, INC. | $16.74 | 2021 | |
| Medtronic, INC. | $14.00 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $13.68 | 2024 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devika Madhavan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.